(Q37928535)

25 August 2017

1 reference

title

mTOR as a therapeutic target in patients with gastric cancer (English)

1 reference

25 August 2017

0 references

3

Atsushi Ohtsu

1 reference

25 August 2017

Salah-Eddin Al-Batran

series ordinal

1

1 reference

PubMed ID

21898386

25 August 2017

Michel Ducreux

series ordinal

2

1 reference

PubMed ID

21898386

25 August 2017

language of work or name

English

0 references

publication date

5 October 2011

1 reference

International Journal of Cancer

25 August 2017

1 reference

25 August 2017

130

1 reference

25 August 2017

491-496

1 reference

25 August 2017

3

1 reference

Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction

25 August 2017

1 reference

Evolving chemotherapy for advanced gastric cancer

21 January 2018

1 reference

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

21 January 2018

1 reference

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer

21 January 2018

1 reference

Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.

21 January 2018

1 reference

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

21 January 2018

1 reference

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

21 January 2018

1 reference

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake

21 January 2018

1 reference

Targeting von Hippel-Lindau pathway in renal cell carcinoma

21 January 2018

1 reference

Upstream and downstream of mTOR

21 January 2018

1 reference

TOR signaling in growth and metabolism

21 January 2018

1 reference

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin

21 January 2018

1 reference

21 January 2018

Expanding mTOR signaling

1 reference

Growing roles for the mTOR pathway

21 January 2018

1 reference

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

21 January 2018

1 reference

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells

21 January 2018

1 reference

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy

21 January 2018

1 reference

The prevalence of PIK3CA mutations in gastric and colon cancer.

21 January 2018

1 reference

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

mTOR Mediated Anti-Cancer Drug Discovery

21 January 2018

1 reference

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

Oncogenic mutations in gastric cancer with microsatellite instability.

21 January 2018

1 reference

Mutations of PIK3CA in gastric adenocarcinoma

21 January 2018

1 reference

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

21 January 2018

1 reference

Relation between outcomes and localisation of p-mTOR expression in gastric cancer.

21 January 2018

1 reference

The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray

21 January 2018

1 reference

Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer

21 January 2018

1 reference

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

21 January 2018

1 reference

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

21 January 2018

1 reference

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

21 January 2018

1 reference

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26396

1 reference

25 August 2017

1 reference

PubMed ID

21898386